Comparison of disk diffusion, E-test and broth microdilution test in determination of susceptibility of Aspergillus species to amphotericin B, itraconazole and voriconazole

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 87-92

  Ozkutuk, Aydan ^a   Ergon, C ^a   Metin, D Y ^b   Yucesoy, M ^a   Polat, S H ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Amphotericin B; Antifungal susceptibility testing; Aspergillus spp.; CLSI M38 A; Disk diffusion; E test; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; FUNGAL STRAIN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 41149122227     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.87     Document Type: Article

References (30)

1. Lionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy 2005; 25(9): 1174-80.
2. Torres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontayiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis. 2003; 46: 25-8.
3. Lass-Flörl C, Kofler G, Kropshofer G et al. In-vitro testing susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497-502.
4. Johnson EM, Oakley KL, Radford SA et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85-93.
5. Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immun 1999; 43: 1017-25.
6. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal Susceptibility Testing: Practical Aspect and Current Challenges. Clin Microbiol Rev. 2001; 14 (4): 643-58.
7. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS document M27-A2. Clinical and Laboratory Standards Institute, Villanova, Pa.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Clinical and Laboratory Standards Institute, Villanova, Pa.
9. Espinel-Ingroff A, Pfaller M, Erwin E, Jones RN. Interlaboratory evaluation of E test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 1996; 34: 848-52.
10. Warnock DW, Johnson EM, Rogers TRF. Multicenter evaluation of the E test method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 321-31.
11. Pfaller MA, Diekema DJ, Messer SA et al. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disc diffusion and E test methods: report from the ARTEMIS global antifungal susceptibility program 2001. J Clin Microbiol 2003; 41: 1440-6.
12. Rementeria A, Sanchez-Vargas LO, Villar M et al. Comparison of tablet and disk diffusion methods for flukonazole and voriconazole in vitro activity testing against clinical yeast isolates. J Chemother 2007; 19: 28-33.
13. Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis. 2003; 16: 527-32.
14. Espinel-Ingroff A. Evaluation of Broth Microdilution Testing Parameters and Agar Diffusion Etest Procedure for Testing Susceptibilities of Aspergillus spp. to Caspofungin Acetate (MK-0991). J Clin Microbiol 2003; 41(1): 403-9.
15. Espinel-Ingroff A, Rezusta A. E-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method. J Clin Microbiol 2002; 40(6): 2101-7.
16. Szekely A, Johnson EM, Warnock DW. Comparison of E test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37: 1480-3.
17. Arikan S, Paetznick V, Rex JH. Comparative Evalution of Disk Diffusion with Microdilution Assay in Susceptibility Testing of Caspofungin againts Aspergillus and Fusarium Isolates. Antimicrob Agents Chemother 2002; 46(9): 3084-7.
18. Serrano MC, Ramirez M, Morilla D et al. A comparative study of the disk diffusion method with the broth microdilution and E test methods for voriconazole susceptibility testing of Aspergillus spp. J Antimicrob Chemother 2004; 53: 739-42.
19. Lopez-Oviedo E, Aller AI, Martin C et al. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: Comparison with CLSI broth microdilution method. Antimicrob Agents Chemother 2006; 50: 1108-11.
20. Patterson TF. New agents for treatment of invasive aspergillosis. Clin Infect Dis 2002; 35: 367-9.
21. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S. Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001; 47: 333-40.
22. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility Testing of Aspergillus flavus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B in Vitro and Outcome In Vivo. Antimicrob Agents Chemother 2001; 45(5): 1456-62.
23. Walsh T, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin. Br J Infect Dis 2003; 188: 305-19
24. National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guideline. NCCLS document M44-A. Clinical and Laboratory Standards Institute, Villanova, Pa.
25. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401-14.
26. Rex JH, Pfaller MA. Has Antifungal Susceptibility Testing Come of Age? Clin Infect Dis 2002; 35: 982-9.
27. Martin-Mazuelos E, Peman J, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365-370.
28. Meletiadis J, Mouton JW, et al. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40: 2876-2885.
29. Singh J, Rimek D, Kappe R. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B. Mycoses 2006; 49:96-103.
30. Espinel-Ingroff A. Comparison of three commercial (Etest, YeastOne and Neo-Sensitabs tablet) and disk diffusion (modified M44-A) assays with reference (CLSI M38-A and M27-A2 microdilution) MICs for testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol 2006; 44 (10): 3616-3622.